Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is
developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer).
The unique combination of activities of BKT140, i.e., the induction of the exit of blood
cells such as stem cells and mature cells from the bone marrow to the peripheral blood,
coupled with specific induction of MM cell death by BKT-140, represents a novel therapeutic
strategy against MM.